biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Fierce biotech

<< Previous

Bullboard Posts

Next >>

Comment by LOOPA441on Apr 19, 2022 4:21pm

172 Views

Post# 34614415

RE:Fierce biotech

Neither party has shared the financial terms of the deal. Bioasis flagged up financial difficulties at the start of the year, warning investors of “a material uncertainty that may raise significant doubt about [its] ability to continue as a going concern.” At that time, Bioasis said it had enough cash to fund its operation “through approximately May 2022.”

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec